Related Studies Sample Clauses

Related Studies. The agreement by the Parties to any Additional Study under this Section 4.4, whether from the outset of the study pursuant to Sections 4.4(a) or 4.4(b), or through either Party’s exercise of its Opt-In Right to an Incremental Study pursuant to Section 4.4(c)(v), shall be deemed an agreement by the Parties to cooperate in any and all related studies necessary for the implementation of such Additional Study or to obtain Drug Approval in the U.S. and all Major Market Countries in the applicable new Indication or new formulation that is the subject of such Additional Study (excluding any related studies that are required exclusively to obtain Drug Approval in the U.S. and not in any Major Market Country) (each such related [ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. study, a “Related Study”). The terms of Section 4.4 shall apply to any Related Study in the same manner that they apply to the Additional Study to which such Related Study relates.
AutoNDA by SimpleDocs
Related Studies. In 1981, Lamport [9] first proposed a remote password authentication protocol for insecure channels, and since then, many authentication protocols have been studied [10–24], in order to enhance security and efficiency. In 2006, Xxxx et al. [10] proposed a password-based user authentication scheme with a light computational overhead using a one-way hash function and exclusive-OR operations. However, Xxxxx et al. [11] pointed out that Xxxx et al.’s scheme [10] could not resist replay and forgery attacks, and then proposed an enhanced scheme. They claimed that their scheme was secure against reply and forgery attacks, and that it provided improved efficiency in the password change process. In 2009, Xxxxxx et al. [12] described how neither the schemes provided by Xxxx et al. [10] and Xxxxx et al. [11] were secure against replay attacks and man-in-the-middle attacks. They also proposed a robust user authentication scheme for the WSN environment. In the same year, Das [13] proposed an enhanced authentication scheme as the basis for Xxxx et al.’s scheme [10]. He insisted that their scheme can resist different types of attacks, such as many logged-in-users with the same login identity attacks, off-line password guessing attacks, stolen-verifier attacks and impersonation attacks. However, Xxxx and Xxxxxxxxxx [14] pointed out in 2010 that Xxx’s scheme [13] could not resist gateway node bypassing attacks and privileged-insider attacks, and thus proposed an improved authentication scheme. In the same year, Xxxxxx et al. [15] demonstrated that Xxx’s scheme [13] and Khan-Alghathbar’s scheme [14] could not resist stolen smart card attacks, and they then proposed a enhanced version. Xxxx and Xxxx [16] also pointed out that Das scheme [13] could not resist parallel session attacks, and did not provide mutual authentication. In 2011, Xxx et al. [17] proposed a user authentication protocol for two-tiered wireless sensor networks, and Yeh et al. [18] proposed an authentication protocol based on elliptic curves cryptography. In 2012, Xxx et al. [19] and Xxx et al. [20] proposed a user authentication and key agreement scheme for WSNs based on the use of a smart card. These were both designed to fulfill various security requirements, such as key agreement, mutual authentication, password protection and prevention against several attacks. In 2014, Xxxx [21] proposed an user authentication scheme based on biometric technique for WSNs. In the same year, Turkanovic´ et al. [22] prop...
Related Studies. A case study conducted about Haagen-Xxxx’s Blue Ocean Strategy (Del Mundo, 2008) determined customer satisfaction through a post-decision behavior quantification. A survey among 90 customers showed the presence of brand loyalty through repeat purchase intent and brand preference. Xxxxxxxxx (2007) conducted a descriptive study on the integrated marketing and public relations campaign of Toyota Motor Philippines. Through the analysis of interviews with three respondents, it was found out that Toyota has an inclination towards horizontal strategy in coordinating with workers. A study on Sun Cellular’s corporate image (Faelnar, 2007) revealed that the company uses advertising materials as their public relations tools and that there’s more positive perception towards the company. The study used key informant interviews and focus group discussions to gather the data. The frame alignment of Smart Communications and their target market on the company’s corporate identity was measured through a key informant interview and a survey with 105 respondents (Xxxxxxx, 2010). The study yielded that both parties view Smart Communications in the same way. These studies focused on the various companies’ campaign and how it affected the corporate image but no studies were made yet about disaster management and how it was perceived by the people.
Related Studies. The agreement by the Parties to any Additional Study under this Section 4.4, whether from the outset of the study pursuant to Section 4.4(a) or (b), or through either Party’s exercise of its Opt-In Right to an Incremental Study pursuant to Section 4.4(c)(v), shall not be deemed an agreement by the Parties to cooperate in any and all related studies necessary for the implementation of such Additional Study or to obtain Drug Approval in the U.S. and all Major Market Countries in the applicable new Indication or new formulation that is the subject of such Additional Study (excluding any related studies that are required exclusively to obtain Drug Approval in the U.S. and not in any Major Market Country) (each such related study, a “Related Study”). Upon the agreement by the Parties to any Additional Study under this Section 4.4, the Parties shall use good faith efforts to discuss and agree on the terms (including design, budget, timeline and rights and obligations upon wind-down or termination) under which they will cooperate in any Related Studies that may be necessary. If, after discussion, the Parties cannot agree on the terms (including design, budget, timeline and rights and obligations upon wind-down or termination) under which they will cooperate in such Related Study, (i) the conducting Party may conduct the Related Study and shall be solely responsible for such conduct and the costs of such Related Study, and (ii) the terms of Section 4.4 shall apply to any such Related Study as if such Related Study is an Incremental Study. If the Parties agree on the terms of any Related Study, the terms of Section 4.4 shall apply to any Related Study in the same manner that they apply to the Additional Study to which such Related Study relates.
Related Studies. Besides the research described so far, we performed a number of other aerosol-related studies, which resulted in papers that were published or are in press. The Gent PM10 sampler was further characterised [Xxxxx et al., 1997]; work was done on the applicability of XRF with capillary optics for analysing aerosol samples [Xxxxxxxx et al., 1997], and on the use of the NMP for individual particle analysis [Xxxxxxxx et al., 1997d]. The elemental mass size distributions, as derived from cascade impactor measurements, were examined for a site near Rome [Maenhaut et al., 1999c] and the long-term data set from SFU samplings on the Antarctic Peninsula was analysed [Xxxxxxx et al., 1998]. The aerosol composition and deposition were examined in eastern Germany [Xxxxxxxxxxx et al., 2000]. Urban aerosols were studied in Cracow, Poland [Xxxxxx et al., 1999, 2000], in Helsinki, Finland [Xxxxxxxx et al., 1999, 2000, 2001a, 2001b, 2001c], and in Budapest, Hungary [Salma et al., 2000a, 2000b, 2000c, 2001a, 2001b, 2001c]. These urban studies were to some extent linked to the EUROTRAC-2 AEROSOL subproject. Furthermore, the work in Helsinki fitted within the EUROTRAC-2 project SATURN.

Related to Related Studies

  • Studies The clinical, pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Company or its subsidiaries that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus were and, if still pending, are being conducted in accordance in all material respects with all statutes, laws, rules and regulations, as applicable (including, without limitation, those administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA). The descriptions of the results of such studies and tests that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus are accurate and complete in all material respects and fairly present the published data derived from such studies and tests, and each of the Company and its subsidiaries has no knowledge of other studies or tests the results of which are materially inconsistent with or otherwise call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor its subsidiaries has received any notices or other correspondence from the FDA or any other foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA with respect to any ongoing clinical or pre-clinical studies or tests requiring the termination or suspension of such studies or tests. For the avoidance of doubt, the Company makes no representation or warranty that the results of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company will be sufficient to obtain governmental approval from the FDA or any foreign, state or local governmental body exercising comparable authority.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Regulatory Filings NYISO and Connecting Transmission Owner shall file this Agreement (and any amendment hereto) with the appropriate Governmental Authority, if required. Any information related to studies for interconnection asserted by Developer to contain Confidential Information shall be treated in accordance with Article 22 of this Agreement and Attachment F to the ISO OATT. If the Developer has executed this Agreement, or any amendment thereto, the Developer shall reasonably cooperate with NYISO and Connecting Transmission Owner with respect to such filing and to provide any information reasonably requested by NYISO and Connecting Transmission Owner needed to comply with Applicable Laws and Regulations.

  • Trials The Ship shall run the following test and trials:

  • Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.

  • Research Support opioid abatement research that may include, but is not limited to, the following:

  • Regulatory Materials (a) Alvogen shall have the sole right to control filing or submission of Regulatory Materials with the Regulatory Agencies in the Territory with respect to Product including the MAA Approval for Product and Regulatory Approvals in the Territory, subject to Section 3.2 and the oversight of and in consultation with the Executive Steering Committee, and [***]Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. shall be responsible for managing all communications and interactions with the Regulatory Agencies in the Territory with respect to Product in the Territory. In all cases, prior to the filing of any Regulatory Materials (including the MAA for Product) for Product with the applicable Regulatory Agency, Alvogen shall provide a copy thereof to Pfenex (through the Executive Steering Committee) for its review and comment. Pfenex shall have fifteen (15) Business Days from the date it receives a copy of any Regulatory Materials with respect to the Product to provide Alvogen with comments regarding such Regulatory Materials, unless the Regulatory Agencies in the Territory or Applicable Law requires that such Regulatory Material(s) be filed on a timeline that does not reasonably permit such advanced notice, in which case Pfenex shall have as much time as is reasonably practicable to provide Alvogen with comments. Alvogen shall consider all such comments in good faith. Alvogen shall, to the extent permitted by Applicable Law, provide Pfenex with (i) reasonable advanced notice (and in no event less than fifteen (15) Business Days’ advance notice whenever feasible) of substantive meetings with any Regulatory Agency in the Territory that are either scheduled with or initiated by or on behalf of Alvogen or its Affiliates, (ii) an opportunity to have a reasonable number (but at least two (2)) representatives participate in all substantive meetings with the Regulatory Agencies in the Territory with respect to Product, and in any case keep Pfenex informed as to all material interactions with the Regulatory Agencies in the Territory with respect to Product, and (iii) a copy of any material documents, information and correspondence submitted to or received from the Regulatory Agencies in the Territory with respect to Product as soon as reasonably practicable.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

Time is Money Join Law Insider Premium to draft better contracts faster.